|
|
|
| Brand | Other Names | Presentation | Strengths | Enquire |
| Remodulin® | treprostinil sodium | Injection | 50 mg/20 mL x 1 vial | |
| Injection | 20 mg/20 mL x 1 vial | |||
| Injection | 100 mg/20 mL x 1 vial | |||
| Injection | 200 mg/20 mL x 1 vial |
| TGA indication | |
| Remodulin is indicated as a continuous subcutaneous infusion for the treatment of pulmonary arterial hypertension in patients with NYHA class III-IV to diminish symptoms associated with exercise. | |
| PBS listing | |
| This product is not listed on the PBS. | |
| Information for Patients | |
| Consumer Medicine Information | |
| Information for Healthcare Professionals | |
| Product Information | |
